Antag Therapeutics Announces €80 Million Series A Financing
Antag Therapeutics, a next-generation biopharmaceutical company pioneering novel treatments for obesity, today announced the closing of an €80 million Series A financing. The round was led by Versant Ventures, with participation from Novo Holdings, SR One, Dawn Biopharma (a platform controlled by KKR), Pictet, Longview Ventures (an affiliate of Broadview
Ventures), and Export and Investment Fund of Denmark (EIFO). The funds will support the clinical development of AT-7687, a novel, once-weekly subcutaneous antagonist of the Glucose Dependent Insulinotropic Polypeptide Receptor (GIPR), and also fueling the expansion of Antag’s pipeline of monthly injectable therapies.
GLP-1-based therapies have revolutionized obesity management, but for some patients can cause tolerability issues, loss of muscle mass, and suboptimal weight-loss. This highlights the need for complementary pharmacological approaches.
